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Introduction
Despite accepted clinical diagnostic criteria overruling
both negative and positive genetic results, Mediterranean
fever gene (MEFV) testing for familial Mediterranean fever
(FMF) is regular practice.
Objectives
This study aimed at identifying the benefits and impact
of this practice.
Methods
Previously diagnosed pediatric patients (N=681), at a ter-
tiary pediatric FMF clinic, were stratified according to the
availability of genetic results at colchicine prescription,
and according to their phenotype, defined as typical or
atypical at colchicine prescription. Subgroups were com-
pared with respect to their genetic features.
Results
At colchicine prescription, genetic results were not avail-
able for 229/681 patients (34%). A typical phenotype was
significantly more common in this subgroup than in
patients with genetic testing at prescription (212/229, 92%,
vs. 260/452, 58%, OR=9.2 95% CI 5.4-15.6, p=0.0001). Of
note, despite the high frequency of typical phenotype in
this group, the rate of 2 pathogenic variants of MEFV was
higher (61.5% vs. 49.3%, p=0.002), the rate of genetic nega-
tive FMF was lower (7% vs. 17.4%, p<0.0001), and the rate
of p.M694V homozygosity tended to be higher (31% % vs.
25, a trend) in those with gene analysis available at
prescription. When focusing on typical presentation alone
(n=472), the distinction between the groups increased, as
in the subgroup with typical phenotype plus genetic analy-
sis prior to prescription the rates of 2 pathogenic variants
and homozygosity to M694V were higher than in typical
phenotype without genetic testing (60.7% vs. 50%, p=0.02,
and 37% vs. 27%, p= 0.037 respectively).
Conclusion
It appears that in real life most FMF patients awaited
genetic testing before colchicine prescription, with parti-
cular predilection to atypical patients. This practice
results in a better match between clinical and genetic
diagnosis of FMF. Of interest, an overall similar distri-
bution of MEFV genotypes in typical and atypical
patients suggests substantial modulation of the MEFV
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